Literature DB >> 20216225

Predicting virologic failure among HIV-1-infected children receiving antiretroviral therapy in Tanzania: a cross-sectional study.

Susan D Emmett1, Coleen K Cunningham, Blandina T Mmbaga, Grace D Kinabo, Werner Schimana, Mark E Swai, John A Bartlett, John A Crump, Elizabeth A Reddy.   

Abstract

BACKGROUND: Many HIV care and treatment programs in resource-limited settings rely on clinical and immunologic monitoring of antiretroviral therapy (ART), but accuracy of this strategy to detect virologic failure (VF) among children has not been evaluated.
METHODS: A cross-sectional sample of HIV-infected children aged 1-16 years on ART >or=6 months receiving care at a Tanzanian referral center underwent clinical staging, CD4 lymphocyte measurement, plasma HIV-1 RNA level, and complete blood count. Associations with VF (HIV-1 RNA >or=400 copies/mL) were determined utilizing bivariable and multivariate analyses; accuracy of current clinical and immunologic guidelines in identifying children with VF was assessed.
FINDINGS: Of 206 children (median age 8.7 years, ART duration 2.4 years), 65 (31.6%) demonstrated VF at enrollment. Clinical and immunological criteria identified 2 (3.5%) of 57 children with VF on first-line therapy, exhibiting 3.5% sensitivity and 100% specificity. VF was associated with younger age, receipt of nevirapine vs. efavirenz-based regimen, CD4% < 25%, and physician documentation of maladherence (P < 0.05 on bivariable analysis); the latter 2 factors remained significant on multivariate logistic regression.
INTERPRETATION: This study demonstrates poor performance of clinical and immunologic criteria in identifying children with virologic failure. Affordable techniques for measuring HIV-1 RNA level applicable in resource-limited settings are urgently needed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20216225      PMCID: PMC4185279          DOI: 10.1097/QAI.0b013e3181cf4882

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  22 in total

1.  What you see may not be what you get: a brief, nontechnical introduction to overfitting in regression-type models.

Authors:  Michael A Babyak
Journal:  Psychosom Med       Date:  2004 May-Jun       Impact factor: 4.312

Review 2.  Laboratory medicine in Africa: a barrier to effective health care.

Authors:  Cathy A Petti; Christopher R Polage; Thomas C Quinn; Allan R Ronald; Merle A Sande
Journal:  Clin Infect Dis       Date:  2005-12-20       Impact factor: 9.079

3.  Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART.

Authors:  Richard E Nettles; Tara L Kieffer; Patty Kwon; Daphne Monie; Yefei Han; Teresa Parsons; Joseph Cofrancesco; Joel E Gallant; Thomas C Quinn; Brooks Jackson; Charles Flexner; Kathryn Carson; Stuart Ray; Deborah Persaud; Robert F Siliciano
Journal:  JAMA       Date:  2005-02-16       Impact factor: 56.272

4.  Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program.

Authors:  Thanyawee Puthanakit; Aurmporn Oberdorfer; Noppadon Akarathum; Suparat Kanjanavanit; Pornphun Wannarit; Thira Sirisanthana; Virat Sirisanthana
Journal:  Clin Infect Dis       Date:  2005-05-24       Impact factor: 9.079

5.  Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team.

Authors:  S E Starr; C V Fletcher; S A Spector; F H Yong; T Fenton; R C Brundage; D Manion; N Ruiz; M Gersten; M Becker; J McNamara; L M Mofenson; L Purdue; S Siminski; B Graham; D M Kornhauser; W Fiske; C Vincent; H W Lischner; W M Dankner; P M Flynn
Journal:  N Engl J Med       Date:  1999-12-16       Impact factor: 91.245

6.  Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Côte d'Ivoire.

Authors:  Patricia Fassinou; Narcisse Elenga; François Rouet; Rockiath Laguide; Kouakou A Kouakoussui; Marguerite Timite; Stephane Blanche; Philippe Msellati
Journal:  AIDS       Date:  2004-09-24       Impact factor: 4.177

7.  Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.

Authors:  F van Leth; P Phanuphak; K Ruxrungtham; E Baraldi; S Miller; B Gazzard; P Cahn; U G Lalloo; I P van der Westhuizen; D R Malan; M A Johnson; B R Santos; F Mulcahy; R Wood; G C Levi; G Reboredo; K Squires; I Cassetti; D Petit; F Raffi; C Katlama; R L Murphy; A Horban; J P Dam; E Hassink; R van Leeuwen; P Robinson; F W Wit; J M A Lange
Journal:  Lancet       Date:  2004-04-17       Impact factor: 79.321

8.  Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy.

Authors:  Moses R Kamya; Harriet Mayanja-Kizza; Andrew Kambugu; Sabrina Bakeera-Kitaka; Fred Semitala; Patricia Mwebaze-Songa; Barbara Castelnuovo; Petra Schaefer; Lisa A Spacek; Anne F Gasasira; Elly Katabira; Robert Colebunders; Thomas C Quinn; Allan Ronald; David L Thomas; Adeodata Kekitiinwa
Journal:  J Acquir Immune Defic Syndr       Date:  2007-10-01       Impact factor: 3.731

9.  Evaluation of the Abbott m2000rt RealTime HIV-1 assay with manual sample preparation compared with the ROCHE COBAS AmpliPrep/AMPLICOR HIV-1 MONITOR v1.5 using specimens from East Africa.

Authors:  John A Crump; Lesley E Scott; Emma Msuya; Anne B Morrissey; Ekyafyose E Kimaro; John F Shao; Wendy S Stevens
Journal:  J Virol Methods       Date:  2009-09-01       Impact factor: 2.014

10.  Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.

Authors:  Anand Reddi; Sarah C Leeper; Anneke C Grobler; Rosemary Geddes; K Holly France; Gillian L Dorse; Willem J Vlok; Mbali Mntambo; Monty Thomas; Kristy Nixon; Helga L Holst; Quarraisha Abdool Karim; Nigel C Rollins; Hoosen M Coovadia; Janet Giddy
Journal:  BMC Pediatr       Date:  2007-03-17       Impact factor: 2.125

View more
  39 in total

1.  Accuracy of immunological criteria for identifying virological failure in children on antiretroviral therapy - the IeDEA Southern Africa Collaboration.

Authors:  Mary-Ann Davies; Andrew Boulle; Brian Eley; Harry Moultrie; Karl Technau; Helena Rabie; Gilles van Cutsem; Janet Giddy; Robin Wood; Matthias Egger; Olivia Keiser
Journal:  Trop Med Int Health       Date:  2011-08-11       Impact factor: 2.622

2.  Burden of disease and risk factors for death among children treated for tuberculosis in Malawi.

Authors:  R J Flick; M H Kim; K Simon; A Munthali; M C Hosseinipour; N E Rosenberg; P N Kazembe; J Mpunga; S Ahmed
Journal:  Int J Tuberc Lung Dis       Date:  2016-08       Impact factor: 2.373

3.  Prediction of treatment failure using 2010 World Health Organization Guidelines is associated with high misclassification rates and drug resistance among HIV-infected Cambodian children.

Authors:  Benjamin P Westley; Allison K DeLong; Chhraing S Tray; Dim Sophearin; Elizabeth M Dufort; Eric Nerrienet; Leeann Schreier; Joseph I Harwell; Rami Kantor
Journal:  Clin Infect Dis       Date:  2012-04-26       Impact factor: 9.079

4.  Early virologic failure and the development of antiretroviral drug resistance mutations in HIV-infected Ugandan children.

Authors:  Theodore D Ruel; Moses R Kamya; Pelin Li; William Pasutti; Edwin D Charlebois; Teri Liegler; Grant Dorsey; Philip J Rosenthal; Diane V Havlir; Joseph K Wong; Jane Achan
Journal:  J Acquir Immune Defic Syndr       Date:  2011-01-01       Impact factor: 3.731

5.  Virologic Response to First-line Efavirenz- or Nevirapine-based Antiretroviral Therapy in HIV-infected African Children.

Authors:  Adeodata Kekitiinwa; Alexander J Szubert; Moira Spyer; Richard Katuramu; Victor Musiime; Tawanda Mhute; Sabrina Bakeera-Kitaka; Oscar Senfuma; Ann Sarah Walker; Diana M Gibb
Journal:  Pediatr Infect Dis J       Date:  2017-06       Impact factor: 2.129

6.  Determinants of virological outcome and adverse events in African children treated with paediatric nevirapine fixed-dose-combination tablets.

Authors:  Andrzej Bienczak; Paolo Denti; Adrian Cook; Lubbe Wiesner; Veronica Mulenga; Cissy Kityo; Addy Kekitiinwa; Diana M Gibb; David Burger; Ann S Walker; Helen McIlleron
Journal:  AIDS       Date:  2017-04-24       Impact factor: 4.177

7.  Antiretroviral drug concentrations in hair are associated with virologic outcomes among young people living with HIV in Tanzania.

Authors:  Zachary J Tabb; Blandina T Mmbaga; Monica Gandhi; Alexander Louie; Karen Kuncze; Hideaki Okochi; Aisa M Shayo; Elizabeth L Turner; Coleen K Cunningham; Dorothy E Dow
Journal:  AIDS       Date:  2018-06-01       Impact factor: 4.177

8.  Comparison of adherence monitoring tools and correlation to virologic failure in a pediatric HIV clinical trial.

Authors:  Jintana Intasan; Torsak Bunupuradah; Saphonn Vonthanak; Pope Kosalaraksa; Rawiwan Hansudewechakul; Suparat Kanjanavanit; Chaiwat Ngampiyaskul; Jurai Wongsawat; Wicharn Luesomboon; Tanakorn Apornpong; Stephen Kerr; Jintanat Ananworanich; Thanyawee Puthanakit
Journal:  AIDS Patient Care STDS       Date:  2014-06       Impact factor: 5.078

9.  Clinical characteristics of pediatric HIV-1 patients treated with first-line antiretroviral therapy in Vietnam: a nested case-control study.

Authors:  Minh Diem Dang; Duc Minh Nguyen; Huu Bich Tran; Viet Hung Pham; Daryl Spak; Linh Chi Pham; Thi Quynh Phan; Thi Thanh Dinh; Thi Kim Anh Le; Van Lam Nguyen; Thanh Hai Le; Son Ngoc Hoang; Vu Phuong Linh Dang
Journal:  Int J Public Health       Date:  2017-02-03       Impact factor: 3.380

10.  Seroprevalence of Hepatitis B and C Viruses Among Children in Kilimanjaro Region, Tanzania.

Authors:  Florida J Muro; Suzanne P Fiorillo; Philoteus Sakasaka; Christopher Odhiambo; Elizabeth A Reddy; Coleen K Cunningham; Ann M Buchanan
Journal:  J Pediatric Infect Dis Soc       Date:  2013-04-12       Impact factor: 3.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.